Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fleischmann

Showing results (111-120 of 160) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|August 24, 2022
Olokizumab versus Placebo or Adalimumab in Rheumatoid ArthritisJosef S Smolen, Eugen Feist, Saeed Fatenejad, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
Arthritis Research & Therapy|August 17, 2018
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritisRoy M Fleischmann, Rieke Alten, Margarita Pileckyte, et al.
The Lancet. Rheumatology|January 22, 2024
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group studyRoy M Fleischmann, Wassim Saikali, Sharad Lakhanpal, et al.
Annals of the Rheumatic Diseases|July 2, 2024
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatmentEugen Feist, Roy M Fleischmann, Saeed Fatenejad, et al.
Annals of the Rheumatic Diseases|January 10, 2013
Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammationBruce W Kirkham, Mary Chester Wasko, Elizabeth C Hsia, et al.
Annals of the Rheumatic Diseases|January 7, 2006
Safety of extended treatment with anakinra in patients with rheumatoid arthritisR M Fleischmann, J Tesser, M H Schiff, et al.
Archives of Internal Medicine|November 22, 1993
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosaS H Roth, E A Tindall, A K Jain, et al.
The Journal of Rheumatology|July 5, 2005
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritisMark C Genovese, Joan M Bathon, Roy M Fleischmann, et al.
Annals of the Rheumatic Diseases|August 1, 2019
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient responseRoy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, et al.
Pageof 16

Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|August 24, 2022
Olokizumab versus Placebo or Adalimumab in Rheumatoid ArthritisJosef S Smolen, Eugen Feist, Saeed Fatenejad, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
Arthritis Research & Therapy|August 17, 2018
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritisRoy M Fleischmann, Rieke Alten, Margarita Pileckyte, et al.
The Lancet. Rheumatology|January 22, 2024
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group studyRoy M Fleischmann, Wassim Saikali, Sharad Lakhanpal, et al.
Annals of the Rheumatic Diseases|July 2, 2024
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatmentEugen Feist, Roy M Fleischmann, Saeed Fatenejad, et al.
Annals of the Rheumatic Diseases|January 10, 2013
Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammationBruce W Kirkham, Mary Chester Wasko, Elizabeth C Hsia, et al.
Annals of the Rheumatic Diseases|January 7, 2006
Safety of extended treatment with anakinra in patients with rheumatoid arthritisR M Fleischmann, J Tesser, M H Schiff, et al.
Archives of Internal Medicine|November 22, 1993
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosaS H Roth, E A Tindall, A K Jain, et al.
The Journal of Rheumatology|July 5, 2005
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritisMark C Genovese, Joan M Bathon, Roy M Fleischmann, et al.
Annals of the Rheumatic Diseases|August 1, 2019
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient responseRoy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, et al.
Pageof 16